Drug Trial Radar · NCT04890795
A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: May 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
237
Planned (sponsor's estimate)
Start
Oct 19, 2020
Primary completion
Sep 2021
Study completion Sep 2021
Sponsor
- Lead sponsor
- Advenchen Laboratories Nanjing Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Based on indicators such as 24 week progression free survival (24 weeks PFS) in small cell lung cancer (SCLC) patients without disease progression after first-line platinum containing chemotherapy, objective response rate (ORR) in SCLC patients with recurrence or progression after first-line platinum containing chemotherapy, and orr in SCLC patients with recurrence or progression after second-line and above treatment,Evaluation of the effectiveness of al8326 monotherapy in small cell lung cancer.
Conditions
- Small Cell Lung Cancer
Interventions
AL8326 tabletsDrug
10mg/tablet;Oral administration, once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- (Group A) 24 weeks progression free survival (24 weeks PFS)Time frame: Every 2 cycles(each cycle is 28--days)
- (Group B and C) Objective response rate (ORR)Time frame: Every 2 cycles(each cycle is 28--days)
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
The first affiliated hospital of bengbu medical college
Bengbu, Anhui, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
General Hospital of Eastern Theater Command
Nanjing, Jiangsu, China · Recruiting
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China · Recruiting
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China · Recruiting
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Sichuan Cancer Hospital
Chengdu, Sichuan, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.